Browse > Article
http://dx.doi.org/10.14348/molcells.2022.0001

The Chromatin Accessibility Landscape of Nonalcoholic Fatty Liver Disease Progression  

Kang, Byeonggeun (Department of Biological Sciences, Institute of Molecular Biology & Genetics, Seoul National University)
Kang, Byunghee (Department of Life Sciences, Pohang University of Science and Technology (POSTECH))
Roh, Tae-Young (Department of Life Sciences, Pohang University of Science and Technology (POSTECH))
Seong, Rho Hyun (Department of Biological Sciences, Institute of Molecular Biology & Genetics, Seoul National University)
Kim, Won (Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul National University College of Medicine)
Publication Information
Molecules and Cells / v.45, no.5, 2022 , pp. 343-352 More about this Journal
Abstract
The advent of the assay for transposase-accessible chromatin using sequencing (ATAC-seq) has shown great potential as a leading method for analyzing the genome-wide profiling of chromatin accessibility. A comprehensive reference to the ATAC-seq dataset for disease progression is important for understanding the regulatory specificity caused by genetic or epigenetic changes. In this study, we present a genome-wide chromatin accessibility profile of 44 liver samples spanning the full histological spectrum of nonalcoholic fatty liver disease (NAFLD). We analyzed the ATAC-seq signal enrichment, fragment size distribution, and correlation coefficients according to the histological severity of NAFLD (healthy control vs steatosis vs fibrotic nonalcoholic steatohepatitis), demonstrating the high quality of the dataset. Consequently, 112,303 merged regions (genomic regions containing one or multiple overlapping peak regions) were identified. Additionally, we found differentially accessible regions (DARs) and performed transcription factor binding motif enrichment analysis and de novo motif analysis to determine new biomarker candidates. These data revealed the gene-regulatory interactions and noncoding factors that can affect NAFLD progression. In summary, our study provides a valuable resource for the human epigenome by applying an advanced approach to facilitate diagnosis and treatment by understanding the non-coding genome of NAFLD.
Keywords
assay for transposase-accessible chromatin using sequencing; biomarker; chromatin accessibility; epigenome analysis; nonalcoholic fatty liver disease;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Kleiner, D.E., Brunt, E.M., Van Natta, M., Behling, C., Contos, M.J., Cummings, O.W., Ferrell, L.D., Liu, Y.C., Torbenson, M.S., Unalp-Arida, A., et al. (2005). Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313-1321.   DOI
2 Langmead, B. and Salzberg, S.L. (2012). Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357-359.   DOI
3 Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., and 1000 Genome Project Data Processing Subgroup (2009). The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078-2079.   DOI
4 Lyu, Z., Ma, M., Xu, Y., Wang, X., Zhu, Y., Ren, W., and Li, T. (2020). Expression and prognostic significance of epithelial tissue-specific transcription factor ESE3 in hepatocellular carcinoma. Int. J. Clin. Oncol. 25, 1334-1345.   DOI
5 Oh, S., Jo, Y., Jung, S., Yoon, S., and Yoo, K.H. (2020). From genome sequencing to the discovery of potential biomarkers in liver disease. BMB Rep. 53, 299-310.   DOI
6 Riggi, N., Knoechel, B., Gillespie, S.M., Rheinbay, E., Boulay, G., Suva, M.L., Rossetti, N.E., Boonseng, W.E., Oksuz, O., Cook, E.B., et al. (2014). EWS-FLI1 utilizes divergent chromatin remodeling mechanisms to directly activate or repress enhancer elements in Ewing sarcoma. Cancer Cell 26, 668-681.   DOI
7 Sanyal, A.J., Van Natta, M.L., Clark, J., Neuschwander-Tetri, B.A., Diehl, A., Dasarathy, S., Loomba, R., Chalasani, N., Kowdley, K., Hameed, B., et al. (2021). Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N. Engl. J. Med. 385, 1559-1569.   DOI
8 Shia, W.J., Pattenden, S.G., and Workman, J.L. (2006). Histone H4 lysine 16 acetylation breaks the genome's silence. Genome Biol. 7, 217.   DOI
9 Sliz, E., Sebert, S., Wurtz, P., Kangas, A.J., Soininen, P., Lehtimaki, T., Kahonen, M., Viikari, J., Mannikko, M., Ala-Korpela, M., et al. (2018). NAFLD risk alleles in PNPLA3, TM6SF2, GCKR and LYPLAL1 show divergent metabolic effects. Hum. Mol. Genet. 27, 2214-2223.   DOI
10 Yoo, T., Joo, S.K., Kim, H.J., Kim, H.Y., Sim, H., Lee, J., Kim, H.H., Jung, S., Lee, Y., Jamialahmadi, O., et al. (2021). Disease-specific eQTL screening reveals an anti-fibrotic effect of AGXT2 in non-alcoholic fatty liver disease. J. Hepatol. 75, 514-523.   DOI
11 Loomba, R., Gindin, Y., Jiang, Z., Lawitz, E., Caldwell, S., Djedjos, C.S., Xu, R., Chung, C., Myers, R.P., Subramanian, G.M., et al. (2018). DNA methylation signatures reflect aging in patients with nonalcoholic steatohepatitis. JCI Insight 3, e96685.   DOI
12 Zhang, Y., Liu, T., Meyer, C.A., Eeckhoute, J., Johnson, D.S., Bernstein, B.E., Nusbaum, C., Myers, R.M., Brown, M., Li, W., et al. (2008). Model-based analysis of ChIP-Seq (MACS). Genome Biol. 9, R137.   DOI
13 Amemiya, H.M., Kundaje, A., and Boyle, A.P. (2019). The ENCODE blacklist: identification of problematic regions of the genome. Sci. Rep. 9, 9354.   DOI
14 Brunt, E.M., Kleiner, D.E., Wilson, L.A., Belt, P., Neuschwander-Tetri, B.A., and NASH Clinical Research Network (CRN) (2011). Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 53, 810-820.   DOI
15 Cholankeril, G., Patel, R., Khurana, S., and Satapathy, S.K. (2017). Hepatocellular carcinoma in non-alcoholic steatohepatitis: current knowledge and implications for management. World J. Hepatol. 9, 533-543.   DOI
16 Gelbart, M.E., Larschan, E., Peng, S., Park, P.J., and Kuroda, M.I. (2009). Drosophila MSL complex globally acetylates H4K16 on the male X chromosome for dosage compensation. Nat. Struct. Mol. Biol. 16, 825-832.   DOI
17 Kim, E., Kim, D., Lee, J.S., Yoe, J., Park, J., Kim, C.J., Jeong, D., Kim, S., and Lee, Y. (2018). Capicua suppresses hepatocellular carcinoma progression by controlling the ETV4-MMP1 axis. Hepatology 67, 2287-2301.   DOI
18 Lake, A.D., Chaput, A.L., Novak, P., Cherrington, N.J., and Smith, C.L. (2016). Transcription factor binding site enrichment analysis predicts drivers of altered gene expression in nonalcoholic steatohepatitis. Biochem. Pharmacol. 122, 62-71.   DOI
19 McLean, C.Y., Bristor, D., Hiller, M., Clarke, S.L., Schaar, B.T., Lowe, C.B., Wenger, A.M., and Bejerano, G. (2010). GREAT improves functional interpretation of cis-regulatory regions. Nat. Biotechnol. 28, 495-501.   DOI
20 Ross-Innes, C.S., Stark, R., Teschendorff, A.E., Holmes, K.A., Ali, H.R., Dunning, M.J., Brown, G.D., Gojis, O., Ellis, I.O., Green, A.R., et al. (2012). Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 481, 389-393.   DOI
21 Schuster, S., Cabrera, D., Arrese, M., and Feldstein, A.E. (2018). Triggering and resolution of inflammation in NASH. Nat. Rev. Gastroenterol. Hepatol. 15, 349-364.   DOI
22 Seki, E., De Minicis, S., Osterreicher, C.H., Kluwe, J., Osawa, Y., Brenner, D.A., and Schwabe, R.F. (2007). TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat. Med. 13, 1324-1332.   DOI
23 Bailey, T.L., Johnson, J., Grant, C.E., and Noble, W.S. (2015). The MEME Suite. Nucleic Acids Res. 43(W1), W39-W49.   DOI
24 Brunt, E.M., Janney, C.G., Di Bisceglie, A.M., Neuschwander-Tetri, B.A., and Bacon, B.R. (1999). Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am. J. Gastroenterol. 94, 2467-2474.   DOI
25 Buenrostro, J.D., Giresi, P.G., Zaba, L.C., Chang, H.Y., and Greenleaf, W.J. (2013). Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position. Nat. Methods 10, 1213-1218.   DOI
26 Elbadawy, M., Yamanaka, M., Goto, Y., Hayashi, K., Tsunedomi, R., Hazama, S., Nagano, H., Yoshida, T., Shibutani, M., Ichikawa, R., et al. (2020). Efficacy of primary liver organoid culture from different stages of non-alcoholic steatohepatitis (NASH) mouse model. Biomaterials 237, 119823.   DOI
27 Govaere, O., Cockell, S., Tiniakos, D., Queen, R., Younes, R., Vacca, M., Alexander, L., Ravaioli, F., Palmer, J., Petta, S., et al. (2020). Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis. Sci. Transl. Med. 12, eaba4448.   DOI
28 Khan, A., Fornes, O., Stigliani, A., Gheorghe, M., Castro-Mondragon, J.A., van der Lee, R., Bessy, A., Cheneby, J., Kulkarni, S.R., Tan, G., et al. (2018). JASPAR 2018: update of the open-access database of transcription factor binding profiles and its web framework. Nucleic Acids Res. 46(D1), D260-D266.   DOI
29 Corces, M.R., Trevino, A.E., Hamilton, E.G., Greenside, P.G., Sinnott-Armstrong, N.A., Vesuna, S., Satpathy, A.T., Rubin, A.J., Montine, K.S., Wu, B., et al. (2017). An improved ATAC-seq protocol reduces background and enables interrogation of frozen tissues. Nat. Methods 14, 959-962.   DOI
30 Marcher, A.B., Bendixen, S.M., Terkelsen, M.K., Hohmann, S.S., Hansen, M.H., Larsen, B.D., Mandrup, S., Dimke, H., Detlefsen, S., and Ravnskjaer, K. (2019). Transcriptional regulation of Hepatic Stellate Cell activation in NASH. Sci. Rep. 9, 2324.   DOI
31 Choi, W.Y., Hwang, J.H., Cho, A.N., Lee, A.J., Jung, I., Cho, S.W., Kim, L.K., and Kim, Y.J. (2020). NEUROD1 intrinsically initiates differentiation of induced pluripotent stem cells into neural progenitor cells. Mol. Cells 43, 1011-1022.   DOI
32 Kim, J.Y., Park, K.J., Hwang, J.Y., Kim, G.H., Lee, D., Lee, Y.J., Song, E.H., Yoo, M.G., Kim, B.J., Suh, Y.H., et al. (2017). Activating transcription factor 3 is a target molecule linking hepatic steatosis to impaired glucose homeostasis. J. Hepatol. 67, 349-359.   DOI